BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
This Quarter Return
+12.16%
1 Year Return
+11.48%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$717M
AUM Growth
–
Cap. Flow
+$717M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
28.86%
Holding
141
New
140
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Biogen
BIIB
|
$29.9M |
| 2 |
Medtronic
MDT
|
$26.5M |
| 3 |
CELG
Celgene Corp
CELG
|
$26M |
| 4 |
Abbott
ABT
|
$23.5M |
| 5 |
Gilead Sciences
GILD
|
$22.9M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 85.27% |
| 2 | Financials | 0.88% |
| 3 | Industrials | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Neurocrine Biosciences
NBIX
$13.8B
| $1.59M | 0.22% |
+40,000
| New | +$1.59M |
|
102
MannKind Corp
MNKD
$1.41B
| $1.56M | 0.22% |
+300,000
| New | +$1.56M |
|
|
IMMU
103
DELISTED
Immunomedics Inc
IMMU
| $1.53M | 0.21% |
+400,000
| New | +$1.53M |
|
|
IPXL
104
DELISTED
Impax Laboratories, Inc.
IPXL
| $1.53M | 0.21% |
+32,600
| New | +$1.53M |
|
|
GEVA
105
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $1.45M | 0.2% |
+14,900
| New | +$1.45M |
|
106
ResMed
RMD
$40.2B
| $1.44M | 0.2% |
+20,000
| New | +$1.44M |
|
|
ABMD
107
DELISTED
Abiomed Inc
ABMD
| $1.43M | 0.2% |
+20,000
| New | +$1.43M |
|
|
SGEN
108
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.41M | 0.2% |
+40,000
| New | +$1.41M |
|
|
QGENF
109
DELISTED
QIAGEN NV
QGENF
| $1.41M | 0.2% |
+60,000
| New | +$1.41M |
|
110
Halozyme
HALO
$8.56B
| $1.31M | 0.18% |
+91,616
| New | +$1.31M |
|
111
Nektar Therapeutics
NKTR
$568M
| $1.28M | 0.18% |
+116,000
| New | +$1.28M |
|
112
Labcorp
LH
$23.1B
| $1.26M | 0.18% |
+10,000
| New | +$1.26M |
|
|
AFFX
113
DELISTED
AFFYMETRIX INC
AFFX
| $1.26M | 0.18% |
+100,000
| New | +$1.26M |
|
114
Assertio
ASRT
$80.4M
| $1.22M | 0.17% |
+54,500
| New | +$1.22M |
|
|
ECYT
115
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $1.19M | 0.17% |
+190,215
| New | +$1.19M |
|
116
Cencora
COR
$56.5B
| $1.14M | 0.16% |
+10,000
| New | +$1.14M |
|
|
NVDQ
117
DELISTED
Novadaq Technologies Inc.
NVDQ
| $1.14M | 0.16% |
+70,000
| New | +$1.14M |
|
118
Xoma
XOMA
$392M
| $1.07M | 0.15% |
+295,000
| New | +$1.07M |
|
|
MDSO
119
DELISTED
Medidata Solutions, Inc.
MDSO
| $981K | 0.14% |
+20,000
| New | +$981K |
|
|
ELGX
120
DELISTED
Endologix Inc
ELGX
| $854K | 0.12% |
+50,000
| New | +$854K |
|
121
Myriad Genetics
MYGN
$593M
| $850K | 0.12% |
+24,000
| New | +$850K |
|
122
Sangamo Therapeutics
SGMO
$157M
| $784K | 0.11% |
+50,000
| New | +$784K |
|
123
Exelixis
EXEL
$10.1B
| $771K | 0.11% |
+300,000
| New | +$771K |
|
|
WCG
124
DELISTED
Wellcare Health Plans, Inc.
WCG
| $732K | 0.1% |
+8,000
| New | +$732K |
|
125
Puma Biotechnology
PBYI
$254M
| $708K | 0.1% |
+3,000
| New | +$708K |
|